Literature DB >> 7848678

Stimulation of HIV type 1 gene expression and induction of NF-kappa B (p50/p65)-binding activity in tumor necrosis factor alpha-treated human fetal glial cells.

W J Atwood1, C S Tornatore, R Traub, K Conant, P D Drew, E O Major.   

Abstract

In vitro, HIV-1 infection of human fetal glial cells initiates a noncytopathic, productive infection that results in a long-term persistence during which the viral genome remains latent. The cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta) reactivate HIV-1 gene expression in these cells, leading to production of infectious virus. Here we show that treatment of human fetal glial cells with TNF-alpha and IL-1 beta increase expression of the reporter gene chloramphenicol acetyltransferase (CAT) when placed under the control of the HIV-1 5' LTR. We also show that treatment of human fetal glial cells with TNF-alpha leads to increased binding of the nuclear transcription factor NF-kappa B (p50/p65) to a consensus kappa B-binding site present in the HIV-1 5'LTR. Our results suggest that TNF-alpha stimulation of HIV-1 gene expression in primary cultures of human fetal glial cells is mediated by an increase in binding of NF-kappa B (p50/p65) to the HIV-1 LTR. This is the first report documenting NF-kappa B-binding activity in primary cultures of human fetal glial cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848678     DOI: 10.1089/aid.1994.10.1207

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  13 in total

Review 1.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

2.  Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy.

Authors:  Hassen S Wollebo; Mahmut Safak; Luis Del Valle; Kamel Khalili; Martyn K White
Journal:  J Neuroimmunol       Date:  2010-12-24       Impact factor: 3.478

3.  Epigenetic regulation of HIV-1 latency in astrocytes.

Authors:  Srinivas D Narasipura; Stephanie Kim; Lena Al-Harthi
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

4.  Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent.

Authors:  Ashok Chauhan
Journal:  Microbes Infect       Date:  2015-06-02       Impact factor: 2.700

5.  Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes.

Authors:  K Conant; M Ma; A Nath; E O Major
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  In vitro modeling of HIV proviral activity in microglia.

Authors:  Lee A Campbell; Christopher T Richie; Yajun Zhang; Emily J Heathward; Lamarque M Coke; Emily Y Park; Brandon K Harvey
Journal:  FEBS J       Date:  2017-11-08       Impact factor: 5.542

7.  NF-kappaB prevents TNF-alpha-induced apoptosis in an oligodendrocyte cell line.

Authors:  Makoto Hamanoue; Akira Yoshioka; Toya Ohashi; Yoshikatsu Eto; Ken Takamatsu
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

8.  Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway.

Authors:  Deborah Carroll-Anzinger; Anvita Kumar; Vyacheslav Adarichev; Fatah Kashanchi; Lena Al-Harthi
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

Review 9.  HIV-1 endocytosis in astrocytes: a kiss of death or survival of the fittest?

Authors:  Ashok Chauhan; Akshay Tikoo; Jankiben Patel; Arwa Mujahid Abdullah
Journal:  Neurosci Res       Date:  2014-09-08       Impact factor: 3.304

10.  Insights into the Gene Expression Profiles of Active and Restricted Red/Green-HIV+ Human Astrocytes: Implications for Shock or Lock Therapies in the Brain.

Authors:  Venkata Viswanadh Edara; Anuja Ghorpade; Kathleen Borgmann
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.